ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – . Following the press release on October 21, 2024 and the plan to transfer a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback